BCIP Life Sciences Associates, LP's Form 4 filing
Xilio Therapeutics, Inc.XLO · filed Dec 10, 2021
- Accession no.
- 0000899243-21-047829
- Filed
- Dec 10, 2021, 8:33 PM ET
- Trade date
- Dec 8-10, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market purchases total $410.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| BCIP Life Sciences Associates, LPCIK 0001702921 | 10% Owner |
| Bain Capital Life Sciences Investors, LLCCIK 0001703031 | 10% Owner |
| Bain Capital Life Sciences Fund II, L.P.CIK 0001773187 | 10% Owner |
| Bain Capital Life Sciences Investors II, LLCCIK 0001796155 | 10% Owner |
| BCLS II Investco, LPCIK 0001818893 | 10% Owner |
| BCLS II Investco (GP), LLCCIK 0001819101 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 8, 2021 | Common Stock | PPurchaseAcquired | +13,458 | $9.62F2 | +$129,474.03 | 2,776,402 | Indirect | |
| Dec 9, 2021 | Common Stock | PPurchaseAcquired | +4,011 | $9.84F3 | +$39,485.09 | 2,780,413 | Indirect | |
| Dec 10, 2021 | Common Stock | PPurchaseAcquired | +21,812 | $9.56F4 | +$208,564.16 | 2,802,225 | Indirect | |
| Dec 10, 2021 | Common Stock | PPurchaseAcquired | +3,188 | $10.24F5 | +$32,638.11 | 2,805,413 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.41 to $9.75, inclusive. The reporting persons undertake to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.53 to $10.00, inclusive.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.07 to $10.00, inclusive.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $10.13 to $10.25, inclusive.
Referenced by the price of 1 transaction in Table I.
Remarks
Exhibit 99.1: Joint Filer Information